The offering provides a short-term cash infusion but does not resolve the fundamental going concern or Nasdaq delisting risks. Monitor the August 25, 2026 Nasdaq compliance deadline closely — failure to regain compliance could trigger a delisting and a further collapse in the stock price. The high short interest (~26.6%) and the premium offering price create potential for a short squeeze, but the persistent dilution and existential risks make this a high-risk, high-volatility event. Traders should watch for any subsequent 8-K filings regarding Nasdaq compliance status or additional capital needs.
Price Chart
Executive Summary
Jupiter Neurosciences is raising approximately $1.74 million in net proceeds through a registered direct offering of 307,692 shares at $6.50 per share, a 25.7% premium to the last closing price of $5.17. The offering is a dilutive capital raise for a clinical-stage biotech with a going concern warning, Nasdaq non-compliance, and a $5M market cap. Proceeds are for working capital and general corporate purposes, but the company's cash is insufficient to fund operations for the next twelve months, making this a critical near-term lifeline. The offering price above market suggests strong investor demand, but the persistent dilution and existential risks dominate the outlook.
Key Facts
- Offering of 307,692 shares at $6.50/share for gross proceeds of ~$2.0M and net proceeds of ~$1.74M.
- Offering price is a 25.7% premium to the last closing price of $5.17 on August 20, 2026.
- Pro forma as-adjusted net tangible book value per share after offering is $2.77, resulting in immediate dilution of $3.73 per share for new investors.
- Company has a going concern opinion from its auditor for fiscal years 2024 and 2025.
- Nasdaq non-compliance with minimum bid price and market value of listed securities requirements; compliance deadline is August 25, 2026.
- Approximately $0.65M of convertible notes remain outstanding under the Yorkville SEPA, with further potential dilution.
- Short interest is ~26.6% of estimated shares outstanding as of July 31, 2026.
- Company has a $5M market cap and has filed 21 offering/registration documents in the last 24 months.
Financial Impact
Net proceeds of ~$1.74M, representing ~35% of the company's $5M market cap. Immediate dilution of $3.73/share for new investors.
Risk Factors
- Going concern risk: company's cash is insufficient for 12 months of operations.
- Nasdaq delisting risk: compliance deadline is August 25, 2026; failure could lead to OTC trading and reduced liquidity.
- Persistent dilution: 21 offering/registration filings in 24 months; additional shares may be issued under the Yorkville SEPA.
- Clinical-stage biotech with no meaningful revenue and significant net losses.
- Low trading volume and small public float ($12.2M) create extreme price volatility risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-039784 |
| Document: 0001493152-26-039784-index-headers.html | 0001493152-26-039784 |
| Document: 0001493152-26-039784-index.html | 0001493152-26-039784 |
| Document: 0001493152-26-039784.txt | 0001493152-26-039784 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G/A | $2.88 | awaiting T+5 | — | $2.86 (−0.69%) |
Sep 24, 2026 4w ago | S-3 | $2.67 $2.55 | ▲ +4.49% | ▲ +4.27% | $2.86 (−7.12%) |
Sep 22, 2026 4w ago | SC 13G | $2.98 $2.58 | ▼ −13.42% | ▼ −12.24% | $2.86 (−4.03%) |
Aug 28, 2026 8w ago | 8-K | $3.54 $3.08 | ▲ +12.99% | ▲ +12.85% | $2.86 (+19.21%) |
Aug 27, 2026 8w ago | 8-K | $4.89 $3.26 | ▲ +33.33% | ▲ +33.60% | $2.86 (+41.51%) |
Aug 24, 2026 9w ago | 8-K | $5.17 $3.35 | ▲ +35.20% | ▲ +34.66% | $2.86 (+44.68%) |
Aug 24, 2026 9w ago | 8-K | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.86 (+49.47%) |
Aug 24, 2026 9w ago | 424B5 | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.86 (+49.47%) |
Jul 27, 2026 13w ago | 8-K | $0.1135 $0.1000 | ▲ +11.89% | ▲ +14.41% | $2.86 (−2419.82%) |
Jul 21, 2026 14w ago | Press Release | $0.1697 $0.1097 | ▼ −35.36% | ▼ −34.36% | $2.86 (+1585.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers